Drug Profile
RG 6047
Alternative Names: ARN 927; GDC-0927; RG-6047; SERD 2; SRN-927Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Aragon Pharmaceuticals
- Developer Genentech
- Class Antineoplastics; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Endometrial cancer; Ovarian cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Breast-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Spain (PO)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Breast-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO)
- 10 Feb 2020 Phase-I development is ongoing for Breast cancer in USA and Spain (PO) (NCT02316509)